133 related articles for article (PubMed ID: 12034182)
1. Mycophenolate mofetil monotherapy in stable liver transplant recipients with progressive renal failure.
Detry O; De Roover A; Honoré P; Delwaide J; Jacquet N; Meurisse M
Transplant Proc; 2002 May; 34(3):782-3. PubMed ID: 12034182
[No Abstract] [Full Text] [Related]
2. Mycophenolate mofetil monotherapy in liver transplantation.
Stewart SF; Hudson M; Talbot D; Manas D; Day CP
Lancet; 2001 Feb; 357(9256):609-10. PubMed ID: 11558493
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil in stable liver transplant patients with calcineurin inhibitor-induced renal impairment: single-center experience.
Garcia CE; Ribeiro HB; Garcia RL; Copstein JL; Padilla JM; Santos TE; Amaral DD; Silva AO; D'Albuquerque LA
Transplant Proc; 2003 May; 35(3):1131-2. PubMed ID: 12947887
[No Abstract] [Full Text] [Related]
5. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation.
Hirose R; Roberts JP; Quan D; Osorio RW; Freise C; Ascher NL; Stock PG
Transplantation; 2000 Jan; 69(2):307-11. PubMed ID: 10670644
[TBL] [Abstract][Full Text] [Related]
6. Delay of hepatitis C recurrence in liver transplant recipients: impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction.
Fasola CG; Netto GJ; Christensen LL; Molmenti EP; Sanchez EQ; Levy MF; Goldstein RM; Klintmalm GB
Transplant Proc; 2002 Aug; 34(5):1561-2. PubMed ID: 12176485
[No Abstract] [Full Text] [Related]
7. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study.
Schlitt HJ; Barkmann A; Böker KH; Schmidt HH; Emmanouilidis N; Rosenau J; Bahr MJ; Tusch G; Manns MP; Nashan B; Klempnauer J
Lancet; 2001 Feb; 357(9256):587-91. PubMed ID: 11558484
[TBL] [Abstract][Full Text] [Related]
8. Renal failure after liver transplantation: outcome after calcineurin inhibitor withdrawal.
Neau-Cransac M; Morel D; Bernard PH; Merville P; Revel P; Potaux L; Saric J
Clin Transplant; 2002 Oct; 16(5):368-73. PubMed ID: 12225434
[TBL] [Abstract][Full Text] [Related]
9. The use of mycophenolate mofetil in liver transplant recipients.
Detry O; de Roover A; Delwaide J; Meurisse M; Honoré P
Expert Opin Pharmacother; 2003 Nov; 4(11):1949-57. PubMed ID: 14596648
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS
Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
[TBL] [Abstract][Full Text] [Related]
11. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
[TBL] [Abstract][Full Text] [Related]
12. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study.
Karie-Guigues S; Janus N; Saliba F; Dumortier J; Duvoux C; Calmus Y; Lorho R; Deray G; Launay-Vacher V; Pageaux GP
Liver Transpl; 2009 Sep; 15(9):1083-91. PubMed ID: 19718632
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept.
Ringe B; Braun F; Lorf T; Canelo R; Schütz E; Sattler B; Ramadori G
Transplant Proc; 1998 Jun; 30(4):1415-6. PubMed ID: 9636573
[No Abstract] [Full Text] [Related]
14. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression.
Ringe B; Braun F; Wietzke P; Oellerich M; Ramadori G
Transplant Proc; 2000 Nov; 32(7):2543. PubMed ID: 11120285
[No Abstract] [Full Text] [Related]
15. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up.
Gavlik A; Demirbas A; Tsaroucha A; Webb MG; Nery JR; Khan MF; Karatzas T; Khan RT; Zucker K; Viciana AL; Miller JA; Tzakis AG
Transplant Proc; 1997 Nov; 29(7):2971-2. PubMed ID: 9365633
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity.
Torras J; Figueras J; Lama C; Fabregat J; Ramos E; Rafecas A; Gil-Vernet S; Pares D; Busquets J; Jaurrieta E
Transplant Proc; 1999 Sep; 31(6):2430. PubMed ID: 10500656
[No Abstract] [Full Text] [Related]
18. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C and mycophenolate mofetil--a clarification.
Fasola CG; Klintmalm GB
Liver Transpl; 2002 Apr; 8(4):411-2; author reply 412-3. PubMed ID: 11965590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
